Abstract-Limited studies have examined the effects of nonsteroidal anti-inflammatory drug (NSAID) use on the risk of chronic kidney disease (CKD), especially in subjects with hypertension. Using National Health Insurance claims data in Taiwan, we conducted a propensity score-matched cohort study to investigate the relationship between NSAID use and CKD in subjects with hypertension. A total of 31 976 subjects were included in this study: subjects not taking any NSAIDs in 2007 (n=10 782); subjects taking NSAIDs for 1 to 89 days in 2007 (n=10 605); and subjects taking NSAIDs for ≥90 days in 2007 (n=10 589). We performed multivariable proportional hazard models to determine the relationship between NSAID use and CKD. The results showed that NSAID use was associated with a 1.18-fold increased risk of CKD in subjects taking NSAIDs for 1 to 89 days; and a 1.32-fold increased risk of CKD in hypertension subjects taking NSAIDs for ≥90 days, compared with subjects not taking any NSAIDs, after controlling for the confounding factors. In subgroup analyses, subjects taking NSAIDs for ≥90 days, >1 defined daily dose per day or taking NSAIDs >15 cumulative defined daily doses had a greater risk of CKD than subjects not taking any NSAID, but not for congestive heart failure, stroke, cancer, osteoarthritis, or rheumatoid arthritis. These results provide supportive evidence that NSAID use is associated with increased risk of CKD in subjects with hypertension. It is important to closely monitor the effects of NSAID use, particularly in patients with hypertension, a susceptible population for CKD. 
T he rising prevalence of chronic kidney disease (CKD) has led to a substantial public health burden around the world, including in Taiwan. 1,2 Moreover, clinically unrecognized CKD can lead to the progression to end-stage renal disease, which usually requires dialysis therapy or renal transplantation and poses a considerable healthcare burden. 3 Therefore, it is of significant importance to determine CKD-related risk factors for slowing or preventing progression to end-stage renal disease.
It has been known that various epidemiological factors such as age, sex, race, medication use, and comorbidity (ie, diabetes mellitus (DM), cardiovascular disease, and hypertension) are associated with the development of CKD. 2, [4] [5] [6] In addition, previous studies have reported that the use of nonsteroidal anti-inflammatory drugs (NSAIDs), one of the most commonly used medications in the world, is associated with adverse effects on renal function. [7] [8] [9] For example, previous findings have suggested that short-term NSAID use has adverse effects on renal function, including sodium retention, estimated glomerular filtration rate (eGFR) alteration, and blood pressure elevation. [10] [11] [12] But the association between NSAID use and CKD risk has remained inconclusive. [13] [14] [15] Moreover, little is known about the effects of NSAID use on CKD among subjects with hypertension, even though they represent one of the most vulnerable populations predisposed to the development of CKD or end-stage renal disease. 16, 17 At present, limited studies have been conducted to investigate the association of NSAID use with CKD among subjects with hypertension. 3, 18 Therefore, in this study we examined the
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effects of NSAID use on the development of CKD among subjects with hypertension using a nationwide propensity scorematched cohort.
Patients and Methods
Data Source
The single-payer National Health Insurance (NHI) program has been at the core of the healthcare system in Taiwan since 1995. Over the years, >98% of the total Taiwanese population has been covered by the NHI program. 19 The National Health Insurance Research Database (NHIRD), derived from the NHI reimbursement claims data, was created for research purposes in 1996. Data used for this study were obtained from the Longitudinal Health Insurance Database for the year 2005 (LHID2005), which was derived from the NHIRD of 2005 and included 1 000 000 individuals (roughly 5% of the total population of Taiwan) randomly sampled from the 2005 NHI Registry for Beneficiaries, and were representative of the original NHIRD (http:// w3.nhri.org.tw/nhird/date_01.html). In detail, the LIHD2005 contains data on subjects' demographic characteristics, disease diagnoses, and prescription records (including types of medication, time of prescription, duration of drug supply, and dosage). This study was approved by the Institutional Review Board of the National Health Research Institutes in Taiwan.
Study Cohort
We identified individuals with hypertension from the LHID2005. In detail, the selection criteria were described as follows: (1) 20 and (4) subjects registered as NHI beneficiaries in 2006; and the exclusion criteria were (1) subjects aged <20 years in 2006; (2) subjects with CKD diagnosis before 2007; (3) subjects developing CKD, but taking erythropoiesisstimulating agents or phosphate binders; or with dialysis during the entire study period. As a result, a total of 94 541 CKD-free subjects with hypertension in 2007 were identified from the LHID2005 for the study. All study subjects were followed-up through December 31, 2011 to record any incident CKD. Figure 1 presents the detailed flow diagram related to the selection of study subjects for this longitudinal cohort study.
Exposure to NSAIDs
Each prescription record in the NHIRD (including the LHID2005) contains types of medication prescribed, time of prescription, and duration of drug supply and dosage. In this study, we defined the length of exposure to NSAIDs use in 2007 based on the date of the prescription plus the duration of the drug supply (total prescription days) in 2007. The total prescription days for any NSAIDs use in 2007 were summed together to represent NSAID exposure time in 2007. We then classified study subjects into 3 groups based on their NSAID exposure time in 2007: (1) subjects taking NSAIDs for ≥90 days; (2) subjects taking NSAIDs for at least 1 day, but <90 days; and (3) subjects not taking any NSAIDs. In addition, we also computed the cumulative defined daily dose (DDD) of NSAID use in 2007; and the average daily dosage of NSAID use (defined as dividing the cumulative DDD by 365), respectively, for further analyses. In particular, the NSAIDs investigated in this study were as follows: (1) 
Study Cohort Matched Using Propensity Score
To control for the effects of potential confounding factors associated with NSAID use, we applied the propensity score method in this study. We computed the propensity score, the predicted probability of a subject taking NSAIDs conditional on his/her observed baseline characteristics, to identify a nonuser group matched with an NSAID user group with a similar demographic and clinical profile. 21, 22 For each NSAID user in the group of subjects taking NSAIDs for ≥90 days, 1 control was adaptively matched for propensity score, within strata defined by age, sex, enrollee category (EC), geographical area, and the Charlson comorbidity index (CCI) score. 23 We took similar steps to match subjects in the group of subjects taking NSAIDs ranging from 1 to 89 days. As described above, a total of 94 541 CKD-free subjects with hypertension in 2007 were identified from the LHID2005 for the study. After matching subjects for propensity score, 31 976 CKD-free subjects with hypertension in 2007 were included for the subsequent analyses.
Definition of Subjects With CKD
The definition for newly diagnosed CKD subjects was determined to be those who had a diagnosis that included the following ICD-9-CM codes in inpatient or outpatient medical claims data from 2008 to 2011 20 : 250.4 (diabetes with renal manifestation), 274.1 (gouty nephropathy), 403.x1 (hypertensive renal disease), 404.x2 (hypertensive heart and renal disease), 440.1 (atherosclerosis of renal artery), 442.1 (other aneurysm of renal artery), 453.3 (venous embolism and thrombosis, renal vein), 572.4 (hepatorenal syndrome), 580 (acute glomerulonephritis), 581 (nephrotic syndrome), 582 (chronic glomerulonephritis), 583 (nephritis and nephropathy, acute/chronic NOS), 584 (acute renal failure), 585 (chronic renal failure), 586 (renal failure, unspecified), 587 (renal sclerosis, unspecified), 593 (other disorders of kidney and ureter), 753.0 (renal agenesis and dysgenesis), 753.1 (cystic kidney disease), 753.3 (other specified anomalies of kidney), 791.0 (proteinuria), and 866 (injury to kidney).
Statistical Analysis
We calculated and compared the distributions of demographic and clinical characteristics of our study subjects across 3 different NSAID exposure groups using the χ 2 test for categorical variables and F-test for continuous variables, respectively. The examined demographic characteristics included age (<40, 40-64, and ≥65 years), sex, EC (I-IV), and geographical area (northern, central, southern, and eastern). Of note, we used EC as a proxy measure to represent the study subjects' socioeconomic status. A detailed description of EC classification is described elsewhere. 24 The clinical characteristics of medical comorbidities (ie, myocardial infarction [MI] , congestive heart failure [CHF], stroke, DM, cancer, systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], osteoarthritis, gout, and calculus of kidney and ureter); medication use in the past year (ie, antihypertensive drugs, statin, aspirin, urate-lowering drugs, and proton pump inhibitors); and the CCI score (=0, 1-2, and ≥3) were also examined in this study. Because the primary outcome of interest was incident CKD in patients with hypertension, moderate or severe renal disease was not included in the CCI score calculation.
Next, we applied Cox proportional hazard models to investigate the relationship of incident CKD with NSAID use and various CKDrelated risk factors (such as MI, CHF, stroke, DM, cancer, SLE, RA, osteoarthritis, gout, calculus of kidney and ureter, past-year medication use of statin and aspirin, and CCI score) in subjects with hypertension. In addition, Cox proportional hazard models were also performed to investigate the relationship between the effects of NSAID use (including number of NSAID use days, average DDD of NSAID use, and cumulative DDD of NSAID use, separately) and the risk of developing incident CKD, with and without adjustment of covariates. The included covariates were MI, CHF, stroke, DM, cancer, SLE, osteoarthritis, RA, gout, calculus of kidney and ureter, hypertension duration, CCI score, number of antihypertension drugs, past-year use of statin, aspirin, calcium channel blockers, β-blockers, renin-angiotensin-aldosterone system blocking agents, thiazide diuretics, urate-lowering drugs, and proton pump inhibitors, respectively. The group of subjects who did not take any NSAIDs was treated as the reference group. To account for the effect of time-varying NSAID use, we calculated total NSAID prescription days from 2007 until either the development of CKD or the end of the study period for each study subject, which was treated as a time-varying covariate and adjusted in analytic models, accordingly. We further performed subgroup analyses to assess whether the NSAID effects were modified by various demographic or clinical characteristics of the study subjects, stratified by MI, CHF, stroke, DM, cancer, osteoarthritis, RA, gout, calculus of kidney and ureter, CCI score, and pastyear medication use of statin, aspirin, renin-angiotensin-aldosterone system blocking agents, urate-lowering drugs and proton pump inhibitors, respectively. Finally, we tested whether the effects of NSAID use interacted with each of the examined demographic or clinical characteristics by adding a product term in the analytic models.
All the analyses were performed using STATA 11.0 software (Stata Corp, College Station, TX) and SAS version 8.2 (SAS institute, Cary, NC). P<0.05 were declared to be statistically significant.
Results
Demographic and Clinical Characteristics of the Study Subjects
The study cohort was composed of 94 541 subjects with hypertension. After subjects were matched for propensity score, a total of 31 976 CKD-free subjects with hypertension in 2007 were included for the subsequent analyses. Table 1 depicts the demographic and clinical characteristics of the 31 976 CKD-free study subjects. The distributions of age, sex, EC, geographical area, and CCI score were not different across the 3 NSAID exposure groups because of propensity score matching. In terms of clinical characteristics, the distributions of stroke, DM, osteoarthritis, RA, SLE, gout, and calculus of kidney and ureter were significantly different across the 3 groups (all P<10 −3 ). Among those, the percentages of SLE, RA, osteoarthritis, gout, and calculus of kidney and ureter were the highest in the group of subjects taking NSAIDs for ≥90 days compared with the other 2 groups. Similarly, a significant difference was observed for past-year medication use of all examined drugs (all P<10 −3 ). Table 2 shows the association of CKD with various CKDrelated risk factors, including NSAIDs use, comorbidity of MI, CHF, stroke, DM, cancer, SLE, osteoarthritis, RA, gout, calculus of kidney and ureter, past-year medication use of statin and aspirin, and CCI score in subjects with hypertension. The results in Table 2 NSAIDs for 30-89 days, and subjects taking NSAIDs for ≥90 days) and a fifth group (subjects not taking any NSAIDs, subjects taking NSAIDs for 1-29 days, subjects taking NSAIDs for 30-89 days, subjects taking NSAIDs for 90-119 days, and subjects taking NSAIDs for ≥120 days), respectively. The results in Table S1 in the online-only Data Supplement show that subjects exposed to longer periods of NSAID use tend to have an increased risk of developing CKD. Moreover, similar results were observed when we treated a time-varying variable, defined as total NSAID prescription days from 2007 until either the development of CKD or the end of the study period, as an additional covariate in the model (Table S1 ).
Association of CKD With Various CKD-Related Risk Factors
Relationship Between NSAID Use and Risk of CKD
In addition to length of NSAID use, we next investigated the relationship between dose of NSAID use and risk of CKD.
The results in Table 3 indicate that compared with nonusers, subjects with NSAID use for ≥90 days had a 32% increased risk of CKD (AHR, 1.32; 95% CI, 1.21-1.44), and subjects with NSAID use for 1 to 89 days had a 18% increased risk of CKD (AHR, 1.18; 95% CI, 1.08-1.29), respectively. When examining the NSAID exposure dose, the risk of CKD development increased by 23% in the group of subjects taking NSAIDs >1 DDD per day, compared with nonusers (AHR, 1.23; 95% CI, 1.13-1.34 for NSAID use >1 DDD per day). Similar results were found when we examined the cumulative DDD of NSAID use in this propensity score-matched study cohort (Table 3) . Figure 2 depicts the results of the subgroup analyses (stratified by MI, CHF, stroke, DM, cancer, osteoarthritis, RA, gout, calculus of kidney and ureter, CCI score and past-year medication use of renin-angiotensin-aldosterone system blocking agents, statin, aspirin, urate-lowering drugs, and proton pump inhibitors, individually). Similar to the findings presented in Table 2 , using nonusers as the reference group, hypertensive patients taking NSAIDs for ≥90 days in 2007 had a greater risk of CKD than subjects taking NSAIDs for 1 to 89 days in 2007 in most examined factors, except for stroke and RA ( Figure 2A) . Likewise, the results also show that subjects taking NSAIDs over 1 DDD per day or taking NSAIDs >15 cumulative DDDs tended to have a greater risk of CKD than their counterparts ( Figures S1 and S2) . Furthermore, the interactive effects of NSAID use and each of the examined factors were also investigated, but no significant interactive effect was found.
Subgroup Analyses of the Effects of NSAID Use on CKD
Discussion
Our results demonstrated that the use of NSAIDs significantly elevated the risk of CKD among subjects with hypertension in this propensity score-matched study cohort. Our findings also suggested that both the NSAID exposing dose and the duration play a role in CKD. In addition to NSAID use, several risk factors (including MI, stroke, DM, RA, gout, calculus of kidney and ureter, past-year medication use of statin and aspirin, hypertension duration and CCI score) were found to be associated with the risk of CKD in this study. Moreover, to increase comparability among the different study groups, we carried out the analyses using propensity score matching, which might reduce the probability that the findings were due to confounding by factors related to the use of NSAIDs. To the best of our knowledge, this is one of the few nationwide longitudinal cohort studies attempting to determine the effects of NSAID use on the increased risk of CKD in patients with hypertension, a vulnerable population predisposed to develop nephropathy. The results from this study are in line with those reported from previous studies, suggesting an association between NSAID use and an increased risk for CKD.
7,13,14,17,25 For example, Gooch et al 17 investigated the effects of NSAID use on the risk for CKD progression in a study cohort of subjects aged >65 years, and showed that high cumulative NSAID use was significantly associated with elevated risk for rapid CKD progression in an elderly community-based cohort. In addition, the results from our subgroup analyses, that is, subjects taking higher dose of NSAIDs tended to have a greater risk of CKD than their counterparts, support the findings reported in a recent meta-analysis study. 13 Moreover, numerous studies have demonstrated that subjects with CKD increase the risk of developing cardiovascular events and highlighted the clinical and public health importance, particularly, the relationship between CKD and future cardiovascular events may lead to an increased population health burden. [26] [27] [28] For example, Go et al 29 investigated the association between the eGFR and the risks of death, cardiovascular events, and hospitalization. They found that reduced eGFR was significantly associated with the development of death, cardiovascular events, and hospitalization. CA indicates cancer; CCB, calcium channel blockers; CCI, Charlson comorbidity index; CHF, congestive heart failure; CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; HR, hazard ratio; HT, hypertension; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; OA, osteoarthritis; RA, rheumatoid arthritis; RAAS, renin-angiotensin-aldosterone system; and SLE, systemic lupus erythematosus. *Crude HR. †Adjusted variables included: NSAID use, MI, CHF, stroke, DM, CA, SLE, OA, RA, gout, calculus of kidney and ureter, HT duration, CCI score, number of anti-HT drugs, past-year use of statin, aspirin, CCB, β-blockers, RAAS blocking agents, thiazide diuretics, urate-lowering drugs, and proton pump inhibitors.
‡Adjusted variables included: NSAID use, MI, CHF, stroke, DM, CA, SLE, OA, RA, gout, calculus of kidney and ureter, HT duration, CCI score, number of anti-HT drugs, past-year use of statin, aspirin, CCB, β-blockers, RAAS blocking agents, thiazide diuretics, urate-lowering drugs, and proton pump inhibitors, and total NSAID prescription days from 2007 until either the development of CKD or the end of the study period.
§Subjects not taking any NSAIDs were used as the reference group. examined the impact of NSAID exposure on renal function in a prospective cohort of subjects with RA. They found that NSAIDs had negative impact on renal function decline only in subjects with advanced renal impairment, specifically, CKD clinical stage >4 at baseline. Conflicting results across various observational studies might logically be because of differences in study populations, study designs or study sample sizes, etc.
In our subgroup analyses, an increased risk of CKD attributable to NSAID use was observed across most examined factors. Of note, subjects with a longer period of NSAID use (≥90 days in 1 year), or who were exposed to more DDDs or cumulative doses (DDDs per day >1 or cumulative DDDs >15) tended to have a greater risk of CKD, compared with the counter groups (subjects with NSAID use for 1-89 days, DDDs per day ≤1 or cumulative DDDs ≤15, respectively). In addition, given the increase in mortality associated with the development of CKD in this high-risk study population, mortality might represent a competing outcome. Thus, we have treated mortality as an outcome and examined the relationship between use of NSAIDs and risk of mortality. The results have suggested that use of NSAIDs may increase risk of mortality in subjects with hypertension (Table S2) .
Several plausible explanations might help to elucidate the observed adverse effect of NSAID use on CKD in patients with hypertension. First, it has been reported that NSAIDs inhibit the activity of the COX isozymes (COX-1 and COX-2), have an influence on decreasing total renal perfusion, and lead to changes in renal blood flow, all of which may worsen edema and elevate blood pressure, particularly in treated hypertensive patients.
33,34 Second, some studies have reported that NSAIDs play a role in elevating systemic vascular resistance and decreasing glomerular filtration rate in predisposed populations, that is, patients with hypertension or osteoarthritis.
35,36 Third, previous reports have provided supportive evidence that COX-2 plays a role in modulating harmful actions of angiotensin II, consequently impacting the regulation of renal function and blood pressure.
37,38
Fourth, previous studies have demonstrated that NSAIDs could increase plasma asymmetrical dimethylarginine level, indicating NSAIDs' impacts on inhibition of renal COX-2 and consequent cardiovascular dysfunction and renal disease progression.
38,39 For example, Kielstein et al 39 documented that systemic infusion of asymmetrical dimethylarginine reduced renal plasma flow and had considerable effects on systemic vascular resistance. In addition, Ahmetaj-Shala et al 40 reported that asymmetrical dimethylarginine was a potential biomarker involved in inhibition of COX-2 in the kidney and elevating cardiovascular risk. Figure 2 . A, Nonsteroidal anti-inflammatory drug (NSAID) use on risk of chronic kidney disease (CKD) in subjects with hypertension (HT), stratified by myocardial infarction (MI), congestive heart failure (CHF), stroke, diabetes mellitus (DM), cancer, osteoarthritis, rheumatoid arthritis, gout, calculus, and Charlson comorbidity index (CCI) score, respectively. B, NSAID use on risk of CKD in subjects with HT, stratified by past-year medication use of renin-angiotensin-aldosterone system (RAAS) blocking agents, statin, aspirin, urate-lowering drugs, and proton pump inhibitors, respectively.
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http://hyper.ahajournals.org/ Downloaded from identified CKD subjects using various definitions. In addition to the definition described above, first, we only included study subjects with medical records from outpatient visits, which was indicated stable CKD subjects; second, we restricted the ICD-9-CM codes to NSAID-related renal disease, specifically, 582, 583, 585, 586, 587 (chronic renal failure), 250. (Table S3) . However, the misclassification of CKD diagnosis might be undifferentiated across different groups of NSAID use. Second, exposure bias may exist because we did not consider over-the-counter (OTC) NSAID use. Similar to many countries, some NSAIDs can be obtained OTC in Taiwan. The ingredients of OTC NSAIDs that subjects can obtain in Taiwan include aspirin, ibuprofen and naproxen. Currently, >98% of total Taiwanese population has been covered by the National Health Insurance program; and the cost of obtaining OTC NSAIDs without prescription is usually higher than the copayment of an outpatient visit.
As the result, most people obtain NSAIDs through prescriptions unless under an urgent condition. Among those OTC NSAIDs, aspirin is not examined in this study because of different therapeutic purposes from most other NSAIDs. For the rare cases of OTC NSAID use, we think this misclassification is undifferentiated across all of the examined NSAIDs groups and may have potentially reduced the estimated risk observed in the study. Third, it was likely that subjects might be taking NSAIDs because of other diseases/symptoms, which could have had a direct influence on their kidney function or renal disease itself, for example, more chances to be diagnosed CKD earlier. Even though we included relevant comorbid medical conditions as covariates in the analyses, we could not fully exclude potential confounding by indication. Moreover, some potential confounding laboratory data, such as serum albuminuria and eGFR levels, were not available in the NHIRD, and it is likely that the observed increased risk might be partially explained by those unmeasured confounders. Fourth, the underlying pathophysiology of NSAID effects on kidney function remains unclear, and further investigation is merited. Fifth, several studies have suggested that vitamin D deficiency or lack of calcium intake might be associated with CKD development and progression as well as cardiovascular events. [41] [42] [43] [44] However, the information about vitamin supplements is not available in this study. Further investigation will be merited to evaluate the association between use of vitamin supplements and CKD development and progression (or with cardiovascular events).
Taken together, the results demonstrate that NSAID use increases the risk of CKD among subjects with hypertension, a high-risk population for CKD, in a propensity score-matched study cohort. These findings underscore the importance of closely monitoring renal function in patients with HT taking NSAIDs. NSAID use should be based on a careful clinical evaluation of benefits and risks, particularly in patients with hypertension. Physicians should take caution when administering NSAIDs to subjects with hypertension or subjects at high risk for CKD. Further investigation is warranted to better understand the underlying mechanisms in relation to the effects of NSAID use on CKD development in vulnerable groups. 
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None. What Is New?
• This is one of the few nationwide longitudinal cohort studies attempting to determine the effects of nonsteroidal anti-inflammatory drug (NSAID) use on the increased risk of chronic kidney disease in patients with hypertension, a vulnerable population predisposed to develop nephropathy.
What Is Relevant?
• The results from this propensity score-matched cohort study provide supportive evidence that NSAID use is associated with increased risk of chronic kidney disease in subjects with hypertension.
Summary
The findings underscore the importance of closely monitoring renal function in patients with hypertension taking NSAIDs. NSAID use should be based on a careful clinical evaluation of benefits and risks, particularly in patients with hypertension. Physicians should take caution when administering NSAIDs to subjects with hypertension or subjects at high risk for chronic kidney disease.
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